These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 2066644

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
    Hadjidakis DI, Raptis SA, Raptis AE, Karaiskos C, Souvatzoglou A, Diamantopoulos EJ.
    Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol Suppl (Copenh); 1987 Nov; 286():9-18. PubMed ID: 2892339
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of octreotide on growth hormone, IGF-I, IGFBP-3, glucagon, cortisol and epinephrine response to insulin-induced hypoglycaemia in insulin-dependent diabetic patients.
    Lunetta M, Di Mauro M, Le Moli R, Nicoletti F.
    Diabetes Metab; 1997 Dec; 23(6):524-7. PubMed ID: 9496559
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma.
    Robben JH, van den Brom WE, Mol JA, van Haeften TW, Rijnberk A.
    Res Vet Sci; 2006 Feb; 80(1):25-32. PubMed ID: 15946716
    [Abstract] [Full Text] [Related]

  • 11. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [Abstract] [Full Text] [Related]

  • 12. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
    Osei K, O'Dorisio TM, Malarkey WB, Craig EL, Cataland S.
    Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340
    [Abstract] [Full Text] [Related]

  • 13. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
    Kirkegaard C, Nørgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H.
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
    [Abstract] [Full Text] [Related]

  • 14. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G, Füessl HS, Burrin JM, Chilvers E, Bloom SR.
    Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
    [Abstract] [Full Text] [Related]

  • 15. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
    Scheen AJ, Gillet J, Rosenthaler J, Guiot J, Henrivaux P, Jandrain B, Lefèbvre PJ.
    Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations.
    Krentz AJ, Boyle PJ, Macdonald LM, Schade DS.
    Metabolism; 1994 Jan; 43(1):24-31. PubMed ID: 8289671
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion.
    Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA.
    Horm Metab Res; 1992 Jul; 24(7):329-32. PubMed ID: 1516889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.